Article Dans Une Revue PLoS Pathogens Année : 2025

Phage therapy for Klebsiella pneumoniae: Understanding bacteria–phage interactions for therapeutic innovations

Résumé

Klebsiella pneumoniae (KP) is a Gram-negative bacterium that commonly resides in the human gastrointestinal tract and can also act as an opportunistic pathogen and cause extra-intestinal infections. KP poses a global health threat because it causes both hospital- and community-acquired infections in immune-competent and immunocompromised hosts. These infections can be multidrug-resistant and/or hypervirulent, making KP infections difficult to treat and deadly. In the absence of effective treatments for recalcitrant KP infections, bacteriophage (phage) therapy is gaining attention as a promising alternative. In this review, we evaluate KP epidemiology and epitope diversity, discuss interactions between KP-targeting phages and their bacterial hosts from an eco-evolutionary perspective, and summarize recent efforts in phage therapy for treating KP infections. We also discuss novel approaches, including genetic engineering and machine learning, as initial steps toward developing KP-targeting phage therapy as a precision medicine approach for an emerging and dangerous pathogen.

Fichier principal
Vignette du fichier
journal.ppat.1012971.pdf (1.84 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-05027834 , version 1 (13-11-2025)

Licence

Identifiants

Citer

Julie Le Bris, Nathalie Chen, Adeline Supandy, Olaya Rendueles, Daria van Tyne. Phage therapy for Klebsiella pneumoniae: Understanding bacteria–phage interactions for therapeutic innovations. PLoS Pathogens, 2025, 21 (4), pp.e1012971. ⟨10.1371/journal.ppat.1012971⟩. ⟨hal-05027834⟩
136 Consultations
261 Téléchargements

Altmetric

Partager

  • More